DE60235155D1 - Monoklonale antikörper gegen molekulare mimetika von meningokokken-b-epitopen - Google Patents

Monoklonale antikörper gegen molekulare mimetika von meningokokken-b-epitopen

Info

Publication number
DE60235155D1
DE60235155D1 DE60235155T DE60235155T DE60235155D1 DE 60235155 D1 DE60235155 D1 DE 60235155D1 DE 60235155 T DE60235155 T DE 60235155T DE 60235155 T DE60235155 T DE 60235155T DE 60235155 D1 DE60235155 D1 DE 60235155D1
Authority
DE
Germany
Prior art keywords
meningokoken
epitopes
molecular mimetics
monoclonal antibodies
menb
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60235155T
Other languages
English (en)
Inventor
Dan Granoff
Gregory Moe
Rino Rappuoli
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Childrens Hospital Oakland Research Institute
Childrens Hospital Oakland Research Center
Original Assignee
Novartis Vaccines and Diagnostics Inc
Childrens Hospital Oakland Research Institute
Childrens Hospital Oakland Research Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines and Diagnostics Inc, Childrens Hospital Oakland Research Institute, Childrens Hospital Oakland Research Center filed Critical Novartis Vaccines and Diagnostics Inc
Application granted granted Critical
Publication of DE60235155D1 publication Critical patent/DE60235155D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/825—Bacteria

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE60235155T 2001-04-17 2002-04-11 Monoklonale antikörper gegen molekulare mimetika von meningokokken-b-epitopen Expired - Lifetime DE60235155D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28455401P 2001-04-17 2001-04-17
US32683801P 2001-10-03 2001-10-03
PCT/US2002/011501 WO2002083711A2 (en) 2001-04-17 2002-04-11 Molecular mimetics of meningococcal b epitopes which elicit functionally active antibodies

Publications (1)

Publication Number Publication Date
DE60235155D1 true DE60235155D1 (de) 2010-03-11

Family

ID=26962673

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60235155T Expired - Lifetime DE60235155D1 (de) 2001-04-17 2002-04-11 Monoklonale antikörper gegen molekulare mimetika von meningokokken-b-epitopen

Country Status (10)

Country Link
US (1) US7534444B2 (de)
EP (1) EP1379272B1 (de)
JP (3) JP2004529643A (de)
CN (1) CN1306956C (de)
AT (1) ATE455793T1 (de)
AU (1) AU2002252638A1 (de)
CA (1) CA2439428C (de)
DE (1) DE60235155D1 (de)
RU (1) RU2322451C2 (de)
WO (1) WO2002083711A2 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2371994C (en) * 1999-02-26 2010-09-28 Guido Grandi Enhancement of bactericidal activity of neisseria antigens with oligonucleotides containing cg motifs
US6977245B2 (en) 1999-04-12 2005-12-20 The United States Of America As Represented By The Department Of Health And Human Services Oligodeoxynucleotide and its use to induce an immune response
CA2373236C (en) 1999-05-19 2014-08-26 Chiron S.P.A. Combination neisserial compositions
AU2000278267A1 (en) 2000-09-01 2002-03-22 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Vibrio cholerae o139 conjugate vaccines
GB0024200D0 (en) * 2000-10-03 2000-11-15 Smithkline Beecham Sa Component vaccine
US7666674B2 (en) 2001-07-27 2010-02-23 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of sterically stabilized cationic liposomes to efficiently deliver CPG oligonucleotides in vivo
AU2002361468A1 (en) * 2001-08-14 2003-03-18 The Government Of The United States Of America As Represented By The Secretary Of Health And Human S Method for rapid generation of mature dendritic cells
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
AU2002366710A1 (en) 2001-12-20 2003-07-09 The Government Of The United States Of America As Represented By The Secretary Of The Department Of USE OF CpG OLIGODEOXYNUCLEOTIDES TO INDUCE ANGIOGENESIS
US8466116B2 (en) 2001-12-20 2013-06-18 The Unites States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of CpG oligodeoxynucleotides to induce epithelial cell growth
US8263091B2 (en) * 2002-09-18 2012-09-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of treating and preventing infections in immunocompromised subjects with immunostimulatory CpG oligonucleotides
WO2005023295A2 (en) * 2003-09-10 2005-03-17 De Staat Der Nederlanden, Vert. Door De Minister Van Vws Naturally processed immunodominant peptides derived from neisseria meningitidis porin a protein and their use
US20070134263A1 (en) * 2004-02-18 2007-06-14 Anderson Annaliesa S Polypeptides for inducing a protective immune response against staphyloococcus aureus
DE102004023906A1 (de) * 2004-05-13 2005-12-22 GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) Verfahren zur Herstellung von chemischen Mikroarrays
ES2352855T3 (es) * 2005-11-30 2011-02-23 International Institute Of Cancer Immunology, Inc. Nuevos compuestos peptídicos del tumor de wilms.
GB0611914D0 (en) * 2006-06-15 2006-07-26 Teti Giuseppe Peptides that mimic non-human cross-reactive protective epitopes of the group Bmeningococcal capsulsar polysaccharide
US10527329B2 (en) 2008-04-18 2020-01-07 Denso Corporation Ejector-type refrigeration cycle device
AU2011294776B2 (en) 2010-08-23 2016-02-04 Wyeth Llc Stable formulations of Neisseria meningitidis rLP2086 antigens
CA2809758C (en) 2010-09-10 2021-07-13 Wyeth Llc Non-lipidated variants of neisseria meningitidis orf2086 antigens
EP2823312B1 (de) * 2012-03-08 2019-08-07 GlaxoSmithKline Biologicals SA In vitro-wirksamkeits basierte assay für protein-basierten meningokokken-impfstoffe
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
EP4043029A1 (de) 2012-03-09 2022-08-17 Pfizer Inc. Neisseria meningitidis-zusammensetzungen und verfahren dafür
ES2685894T3 (es) 2013-03-08 2018-10-15 Pfizer Inc. Polipéptidos de fusión inmunogénicos
MX369534B (es) 2013-09-08 2019-11-11 Pfizer Composiciones de neisseria meningitidis y sus metodos.
RU2723045C2 (ru) 2015-02-19 2020-06-08 Пфайзер Инк. Композиции neisseria meningitidis и способы их получения
MX2019009011A (es) 2017-01-31 2019-09-26 Pfizer Composiciones de neisseria meningitidis y metodos respectivos.

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4356170A (en) * 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
EP0145359B1 (de) 1983-11-21 1991-01-16 The Wellcome Foundation Limited Komplexe, Verfahren zu ihrer Herstellung und dieselben enthaltende Formulierungen
US4727136A (en) * 1985-10-01 1988-02-23 Canadian Patents And Development Ltd. Modified meningococcal group B polysaccharide for conjugate vaccine
US4970070A (en) * 1986-02-07 1990-11-13 Genetic Systems Corporation Protective monoclonal antibody compositions for infections due to group B streptococcus
ATE120093T1 (de) 1988-12-19 1995-04-15 Praxis Biolog Inc Meningococcales klasse i-aussenmembranprotein- vakzin.
US5128460A (en) * 1989-04-04 1992-07-07 Genelabs Incorporated Recombinant trichosanthin and coding sequence
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
EP0504202B1 (de) * 1989-12-14 1995-05-03 National Research Council Of Canada Verbessertes meningokokkale polysaccharidkonjugatvakzin
US5510264A (en) * 1993-09-28 1996-04-23 Insight Biotech Inc. Antibodies which bind meningitis related homologous antigenic sequences
GB9422096D0 (en) 1994-11-02 1994-12-21 Biocine Spa Combined meningitis vaccine
US5811102A (en) * 1995-06-07 1998-09-22 National Research Council Of Canada Modified meningococcal polysaccharide conjugate vaccines
WO1998008874A1 (en) * 1996-08-27 1998-03-05 Chiron Corporation Monoclonal antibodies that define unique meningococcal b epitopes and their use in the preparation of vaccine compositions
WO1998008543A1 (en) 1996-08-27 1998-03-05 Chiron Corporation Neisseria meningitidis serogroup b glycoconjugates and methods of using the same
ATE421527T1 (de) * 1997-08-27 2009-02-15 Novartis Vaccines & Diagnostic Molekular-mimetika von meningokokkus b epitopen
EP2261346A3 (de) * 1998-05-01 2012-01-04 Novartis Vaccines and Diagnostics, Inc. Antigene und Zusammensetzungen gegen Neisseria meningitidis
CA2371994C (en) 1999-02-26 2010-09-28 Guido Grandi Enhancement of bactericidal activity of neisseria antigens with oligonucleotides containing cg motifs
EP2278007B1 (de) 1999-04-30 2014-04-16 Novartis Vaccines and Diagnostics S.r.l. Konservierte Antigene aus Neisseria
DK1947187T5 (da) * 2000-02-28 2011-10-24 Novartis Vaccines & Diagnostic Hybrid ekspression af neisserial-proteiner

Also Published As

Publication number Publication date
CN1306956C (zh) 2007-03-28
AU2002252638A1 (en) 2002-10-28
JP2010011868A (ja) 2010-01-21
CA2439428C (en) 2012-01-24
JP2008259503A (ja) 2008-10-30
CA2439428A1 (en) 2002-10-24
ATE455793T1 (de) 2010-02-15
CN1602204A (zh) 2005-03-30
WO2002083711A3 (en) 2003-11-06
RU2003133300A (ru) 2005-04-20
EP1379272B1 (de) 2010-01-20
EP1379272A4 (de) 2005-12-14
RU2322451C2 (ru) 2008-04-20
WO2002083711A2 (en) 2002-10-24
JP5215275B2 (ja) 2013-06-19
US20040013686A1 (en) 2004-01-22
EP1379272A2 (de) 2004-01-14
JP2004529643A (ja) 2004-09-30
US7534444B2 (en) 2009-05-19

Similar Documents

Publication Publication Date Title
DE60235155D1 (de) Monoklonale antikörper gegen molekulare mimetika von meningokokken-b-epitopen
CY1113020T1 (el) Εμβολια συνδυασμου για neisseria meningitidis
RU2006140958A (ru) Иммунизация против менингококков серогруппы y с помощью белков
GEP20053691B (en) Multivalent Meningococcal Polysaccharide-Protein Conjugate Vaccine
ATE505478T1 (de) Molekular-mimetika von meningokokkalen b epitopen
DE60015084D1 (de) Verbesserung der bakterizidaktivität von neisseria antigenen mit cg enthaltende oligonukleotiden
CY1109202T1 (el) Συνθεσεις που περιεχουν αντιγονα απο τους οροτυπους b και c της neisseria meningitidis οπως και επιπλεον αντιγονα απο τον οροτυπο α
JP2007533729A5 (de)
BR0015961A (pt) Antìgeno de neisseria de 85kda
DE60230482D1 (de) Antikörper gegen nichtfunktionelle p 2 x 7 rezeptoren, diagnose und behandlung von krebs und anderen leiden
ATE302411T1 (de) Diagnose, prophylaxe und behandlung von morbus crohn durch die verwendung des ompc antigens
BR9906927A (pt) Proteìnas de neisseria meningitidis
MXPA05009351A (es) Conjugados de polisacarido-proteina portadora adhesina superficial de estafilococo para inmunizacion contra infecciones nosocomiales.
SI1725872T1 (sl) Analiza saharidnih cepiv brez interference
BRPI0510440A (pt) conjugados meningocócicos combinados com proteìna carreadora em comum
NO902280D0 (no) Ny poroes farmasoeytisk form og fremstilling derav.
MA29459B1 (fr) Vaccins
BRPI0500090A (pt) Composição de acabamento
HK1085646A1 (en) Antigenic compositions for immunization of non-human mammals against streptococcus equi
DE60036692D1 (de) Zusammensetzungen und methoden zur detektion einer trypanosoma cruzi infektion
TR200003467T2 (tr) Neisseria meningitidis antijenik polipeptidler, mütekabil polinükleotidler ve koruyucu antikorlar
NO20006087L (no) Fremgangsmåter for å öke nivåer av acetylcholin
DK1626726T3 (da) Anvendelse af lornoxicam eller lornoxicam-analoger
ATE204761T1 (de) Pharmazeutische antigen-/antikörperpräparation

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
R082 Change of representative

Ref document number: 1379272

Country of ref document: EP

Representative=s name: UEXKUELL & STOLBERG, 22607 HAMBURG, DE